A specific marker of severe bacterial infection and sepsis

Fully adapted for emergency conditions, VIDAS® B.R.A.H.M.S. PCTaids physicians in making rational clinical decisions and allows optimized patient management. Results are available in only 20 minutes.

Procalcitonin has been demonstrated to:

  • Help assess the severity and prognosis of an infection
  • Support early diagnosis of sepsis
Add to my selection

Do you need more information

Procalcitonin (PCT) helps differentiate bacterial from viral infections, the early detection of an elevated PCT level in patients with suspected bacterial infections enabling earlier antibiotic treatment. PCT also supports informed decisions on when to continue or stop antibiotics, improving patient care and decreasing antibiotic misuse and resistance.

VIDAS® B.R.A.H.M.S PCT is an automated test for the determination of procalcitonin (PCT) in human serum or plasma.

Early Diagnosis and Monitoring

  • Early and highly specific marker for severe bacterial infection

Procalcitonin (PCT) is detected in the blood stream within 3 to 6 hours after an infectious challenge. It is upregulated in response to bacterial but not viral infections. The marker’s level rises with increasing severity of infection, and returns to normal as the infection resolves.

  • Useful tool to monitor treatment efficacy

PCT has a half-life of 24 hours. In adults, levels decrease daily by around 50% if the bacterial infection is controlled by the immune system supported by effective antibiotic therapy. Non-decreasing levels may point to treatment failure.

Kinetic profiles of different biomarkers of bacterial infection  - Click to enlarge 

(adapted from Meisner et al., 19991)


PCT impact on Antibiotic Therapy

Use of Procalcitonin in CRITICAL CARE: SEPSIS

In clinical studies including more than 1,000 ICU patients it has been demonstrated that the application of a decision algorithm based on the relative decrease of plasma PCT levels over time allows a significant reduction in the duration of antibiotic therapy and the length of ICU stay, without apparent harm to patients with severe sepsis and septic shock2,3.

Procalcitonin-based algorithm for the decision to continue or stop antibiotics for patients
with sepsis in intensive care units - Click to enlarge  

(adapted from Bouadma et al., 20104 and Schuetz et al., 20115)


Due to the high specificity of PCT for bacterial infection, PCT measurement at relatively low concentrations can identify patients with clinically relevant bacterial infection of the lower respiratory tract (LRTI) who require antibiotic therapy6,7.

Procalcitonin-based algorithm for the decision to start antibiotics for patients
with suspected low or moderate risk LRTI - Click to enlarge 

(adapted from Schuetz et al., 20115)

Data from multicenter randomized controlled trials in more than 1,000 patients with LRTI could demonstrate that with this approach, antibiotic exposure could be reduced by 65% in a primary care setting6. Importantly, there was no impairment of the patient outcome compared to standard treatment6.

Click to enlarge 


Assessment of Severity and Prognosis

It has been demonstrated that increased PCT values are the best indicator for the severity of infection and organ dysfunction8. As PCT levels correlate with severity of infection (as assessed by SOFA/Sequential Organ Failure Assessment score), an increase in PCT indicates progression of sepsis.

Assessment of severity of disease (increasing organ dysfunction) by PCT
(adapted from Meisner M.9)


Solution adapted to Emergency Settings

Choose VIDAS® B.R.A.H.M.S PCT to take advantage of key benefits:

  • Rapid result: 20 minutes
  • Ease-of-use:
    • Fully automated test on bench top VIDAS® instrument
  • Cost-effective solution:
    • Single-dose format
    • All reagents included in the kit
    • Monthly calibration
  • VIDAS® B.R.A.H.M.S PCT is part of a large VIDAS® Emergency Diagnostic solution, which also includes markers of cardiac necrosis, heart failure and thrombosis

Not all of the products are FDA cleared.
FDA cleared products may not be cleared for all indications mentioned on this site.
Product claims may differ from country to country on regulations and approvals. Please contact your country representative for further details.



  1. Meisner M., J Lab Med 1999;23:263-72
  2. Kopterides P et al., Crit Care Med 2010; 38: 2229-41
  3. Schuetz P et al., Expert Rev Anti Infect Ther 2010, 8(5):575-587
  4. Bouadma et al., Lancet 2010;375: DOI:10.1016/S0140-6736(09)61879-1
  5. Schuetz P et al., Arch Intern Med 2011;171:1322-1331
  6. Schuetz P et al., Clin Infect Dis, 55: 651-662
  7. Christ-Crain M et al., Lancet 2004, 363: 600-607
  8. Harbarth S et al., Am J Respir Crit Care Med 2001,164 :396-402
  9. Meisner et al., Crit Care 1999, 3:45-50

Technical specifications for VIDAS® B.R.A.H.M.S. PCT™

Reference 30450
Tests / kit 60
Sample type Plasma (Lithium heparinate) or serum
Sample volume 200 uL
Time to result 20 minutes
Measuring Range 0.05 - 200ng/mL
Calibration stability 28 days


Find more technical details on www.myvidas.com.


Consult your local bioMérieux representative for product availability in your country.

Related publications


Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012


PCT Decisional Algorithm slide ruler

Can be downloaded from www.myvidas.com. Register now!

Useful links

Sepsis Know From Day 1

World Sepsis Day


Find more scientific and educational resources on www.myvidas.com.

Pioneering Diagnostics